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ABSTRACT
Replication of human immunodeficiency virus 1 (HIV-
1) involves conversion of its single-stranded RNA
genome to double-stranded DNA, which is integrated
into the genome of the host. This conversion is
catalyzed by reverse transcriptase (RT), which pos-
sesses DNA polymerase and RNase H domains. The
available crystal structures suggest that at any given
time the RNA/DNA substrate interacts with only one
active site of the two domains of HIV-1 RT. Unknown
is whether a simultaneous interaction of the sub-
strate with polymerase and RNase H active sites is
possible. Therefore, the mechanism of the coordi-
nation of the two activities is not fully understood.
We performed molecular dynamics simulations to
obtain a conformation of the complex in which the
unwound RNA/DNA substrate simultaneously inter-
acts with the polymerase and RNase H active sites.
When the RNA/DNA hybrid was immobilized at the
polymerase active site, RNase H cleavage occurred,
experimentally verifying that the substrate can simul-
taneously interact with both active sites. These find-
ings demonstrate the existence of a transient confor-
mation of the HIV-1 RT substrate complex, which is
important for modulating and coordinating the enzy-
matic activities of HIV-1 RT.
INTRODUCTION
The proliferation of human immunodeficiency virus 1
(HIV-1) strictly relies on the conversion of its single-
stranded RNA to double-stranded DNA that can be inte-
grated into the host cell genome (1–4). This process is called
reverse transcription and involves RNA-dependent synthe-
sis of the (-)DNA strand with concomitant degradation of
the template RNA, followed by the DNA-dependent syn-
thesis of (+)DNA. Both enzymatic activities that are re-
quired to complete this complex reaction derive from a sin-
gle protein: HIV-1 reverse transcriptase (HIV-1 RT). DNA
strands are synthesized by the polymerase domain of HIV-
1 RT. The RNase H domain degrades the RNA strand of
the RNA/DNA intermediate but also enables appropriate
generation of the RNA primers, termed polypurine tracts
(PPTs), which are necessary for the initiation of DNA syn-
thesis.
Structural and biochemical studies of HIV-1 RT indi-
cate spatial and temporal coordination of the two activi-
ties (5). The position of RNase H cleavage is determined by
interactions between the nucleic acid and polymerase do-
main. For example, in DNA 3′-end-directed cleavage, the
RNA strand of the RNA/DNA substrate is cleaved ∼18
nucleotides from the recessed 3′-end of the DNA that is
bound by the polymerase domain (6,7). This cleavage is
known to occur concomitantly with DNA polymerization,
albeit less frequently than nucleotide incorporation, with
approximately one RNase H cut for each 7 nucleotides that
are added to the growing DNA chain (8,9). During this
polymerization-dependent mode, RNase H cleavage occurs
more efficiently when polymerization pauses (10–12). This
was considered evidence that the substrate needs to be re-
leased from the polymerase active site for the RNase H cuts
to occur. After polymerization is completed, longer RNA
fragments that remain associatedwithDNAare removed by
polymerization-independent RNA 5′-end-directed and in-
ternal cleavage (13–15).Moreover, RNaseH activity strictly
depends on the structural context of the whole enzyme, and
the isolated RNase H domain exhibits minimal activity be-
cause it cannot bind the substrate on its own (16,17).
HIV-1 RT is a heterodimer that consists of two subunits.
The larger subunit, termed p66, possesses polymerase and
RNase H activities. The smaller subunit, termed p51, is a
shorter version of p66 that lacks most of the RNase H do-
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main sequence as a result of processing by HIV-1 protease.
It has an altered conformation and plays a structural role
in the heterodimer (4). In the available crystal structures of
HIV-1 RT two conformations of the nucleic acid substrate
are observed (18–20) (Figure 1). In polymerasemode, the 3′-
end of the primer is bound at the polymerase active site and
aligned for extension with the incoming nucleotide. How-
ever, the scissile phosphate of the RNA strand of the hy-
brid faces away from the active site of RNase H and is lo-
cated too far from it for hydrolysis to occur (e.g. PDB ID:
4PQU) (20). RNase H mode is observed in structures that
are solved in the presence of non-nucleoside RT inhibitors
and with geometry-altering modifications of the substrate
(19,20). In these structures, the unwound substrate does not
interact with the polymerase active site, and the configura-
tion of the RNA strand at the RNase H active site is nearly
catalytic (e.g. PDB ID: 4B3O) (19). These structural data
indicate that conformational changes in the substrate likely
serve to restrict access of the substrate to the RNase H ac-
tive site, thereby restricting the amount of RNase H activ-
ity which is crucial for the proper execution of reverse tran-
scription (19). Although interactions with the polymerase
and RNase H active sites may be mutually exclusive events
in the ground state, the complexmay be able to reach a high-
energy conformation that is conducive to simultaneous cat-
alytic interactions with both sites (i.e. simultaneous mode)
as a minor populated state during genuine thermal fluctua-
tions (Figure 1).
To investigate the mechanism of coordination between
polymerase and RNase H activity, we used molecu-
lar dynamics (MD) simulations to determine whether
RNA/DNA can simultaneously interact with both active
sites of HIV-1 RT. We found that this can occur and that
the corresponding substrate conformation involves mostly
untwisting of the hybrid in the region of the substrate that
interacts with the RNase H domain. To demonstrate the si-
multaneous binding of RNA/DNA at the two active sites
experimentally, we used chemical cross-linking methodol-
ogy to immobilize the substrate at the polymerase active
site. We found that the substrate within cross-linked com-
plexes effectively interacted with the RNase H active site.
These findings reveal a mechanism of modulation and co-
ordination of the enzymatic activity of HIV-1 RT.
MATERIALS AND METHODS
Molecular dynamics simulations
All of the simulations were performed with a ff99bsc0OL3
force field for RNA (21–23), ff99bsc0 OL1 force field for
DNA (21–22,24), and ff12SB force field for protein (21,25–
26). The starting structure for the simulation was obtained
by a series of short simulations of the 4PQU structure, in
which we used molecular modeling to extend the substrate
by 4 base pairs (bp), add a missing protein helix of the
RNaseHdomain (amino acids [aa] 546–554; taken from the
1RTD structure), and revert the crystallographic mutation
D498N. Utilizing this structure, we then used molecular
modeling to alter the sequence of the nucleic acid substrate
tomatch theCL3 hybrid.We also introduced twoMg2+ ions
at the active site of the HIV-1 RNase H domain, based on
the structure with the inhibitor -thujaplicinol and Mn2+
ions (PDB ID 4QAG) (27). The standard simulation pro-
tocol for protein/RNA complexes was followed (28). After
eachmodeling intervention in the structure, a standardmin-
imization and equilibration protocol was used to stabilize
the new structure before resuming the production simula-
tion.
In the simulation, we imposed a series of flat-well re-
straints that are necessary to support a long-term catalytic
interaction of the substrate with the RNase H domain. The
restraints were based on the assumption that interactions
between the substrate and the RNase H domain should
be very similar to those observed in the structures of sub-
strate complexes of cellular RNases H1 (29,30). The first
restraint was the maximum distance of 7.2 A˚ between the
C- of Asp443 at the heart of the active site and the phos-
phorus atom of the hydrolyzed phosphate of the RNA (be-
tween nt +1 and −1). A pair of restraints was then imposed
to recapitulate a critical interaction between the backbone
of the DNA strand and an RNase H element, termed the
phosphate-binding pocket (29,30). A non-bridging oxygen
of the phosphate group that was 2 bp from the scissile phos-
phate (nucleotide−3) was restrained at maximum distances
of 5.8 A˚ fromC- of Thr473 and 5.3 A˚ fromC- of Lys476.
For the restraints, we used a function that imposes no en-
ergy penalty when the interatomic distance is shorter than
the specified maximum distances. The energy penalty lin-
early increases for distances greater than the specified max-
imum distances. We emphasize that these restraints were
fully justified and did not affect any of our conclusions be-
cause the goal of the simulations was to assess the com-
patibility of the substrate with this target geometry. The re-
straints thus helped obtain structural conditions that were
equivalent to our cross-linking experiments within an af-
fordable computational time and in the absence of a suit-
able experimental starting geometry. Currently, there are no
experimental structures that capture simultaneous interac-
tions of the substrate with the polymerase and RNase H
domains of HIV-1 RT that could serve as suitable starting
structures for MD simulations. The spontaneous, unaided
formation of a catalytic site and binding of Mg2+ were be-
yond the timescale of conventional simulations. We also as-
sumed that the appropriate catalytically active arrangement
was not the dominantly populated ‘ground-state’ confor-
mation of the complex.
Protein expression and purification
Genes that encode the p66 and p51 subunits of HIV-1 (iso-
late HXB2) RTwere cloned into pET15 and pET28, respec-
tively. The p51 subunit contained anN-terminal His-tag. To
avoid non-specific cross-linking, Cys282 in both subunits
was substituted with serine. Mutagenesis of the constructs
was performed according to Stratagene’s QuikChange pro-
tocol.
The two subunits were expressed in Escherichia coli BL21
Rosetta cells that were induced with 0.4 mM 1-thio--D-
galactopyranoside at 16◦C. The cells were then harvested
and suspended in 40 mM NaH2PO4 (pH 7.0), 100 mM
NaCl, 5% glycerol, 10 mM imidazole and 1.4 mM -
mercaptoethanol and incubated on ice in the presence of
1 mg/ml lysozyme and protease inhibitor cocktail. Follow-
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Figure 1. Three modes of HIV-1 interaction with an RNA/DNA substrate. The p66 subunit is shown in orange, with the RNase H domain indicated with
a darker shade. The polymerase and RNase H active sites are represented by purple and green circles, respectively. DNA and RNA strands of the hybrid
substrate are shown in blue and red, respectively.
ing sonication, the cleared lysate was loaded onto aHisTrap
column (GEHealthcare) that was equilibrated with 40 mM
NaH2PO4 (pH 7.0), 500 mM NaCl, 5% glycerol, 10 mM
imidazole and 1.4 mM -mercaptoethanol. After a wash
step with 60 mM imidazole, the protein was eluted with 300
mM imidazole. The eluted fraction was dialyzed overnight
against 40 mMNaH2PO4 (pH 7.0), 50 mMNaCl, 5% glyc-
erol, 0.5 mM ethylenediaminetetraacetic acid (EDTA) and
0.5 mM dithiothreitol (DTT) and loaded on a Heparin col-
umn (GE Healthcare) that was equilibrated with the same
buffer. Protein was eluted with a linear gradient of 50–500
mM NaCl. Selected fractions were pooled and applied to
a Superdex 200 column (GE Healthcare) that was equili-
brated with 20 mM Tris (pH 8.0), 100 mM NaCl, 5% glyc-
erol, 0.5 mM EDTA and 0.5 mM DTT. Selected fractions
were pooled and concentrated.
Chemically modified DNA oligonucleotides
DNA oligonucleotides that carried the 2-F-dI residue
at the desired position of the through-base modification
were ordered from Metabion (Martinsried, Germany).
The oligonucleotides were reacted with cystamine
(NH2CH2CH2S-SCH2CH2NH2) whose amine group
substituted the fluorine atom in the base, producing
thiol-modified DNA. Synthesis columns that contained
the oligonucleotides were first deprotected with 3%
dichloroacetic acid and washed with dichloromethane. The
columns were incubated with cystamine dihydrochloride
solution in trimethylamine/water (3:5) for 18 h with
occasional agitation. The solution was collected from the
column and dried using a speed vacuum, and the pellet
was suspended in 1 ml of ammonia/40% methylamine (1:1;
AMA). The columns were incubated with 1 ml of AMA
solution for 2 h with occasional agitation. The washing
solution was collected. Both fractions were incubated at
60◦C for 20 h and dried using a speed vacuum. The pellets
were resuspended in water, pooled and loaded on a DNA-
Pac PA100 column (Dionex) that was equilibrated with
4 M urea, 20 mMMES (pH 6.5), 1 mM NaClO4 and 0.2%
acetonitrile at 65◦C. Elution was performed with a linear
gradient of 1–400 mM NaClO4. DNA from the selected
fractions was retrieved by ethanol precipitation and further
purified on 12% denaturing TBE-urea polyacrylamide gel.
Purified oligonucleotides were stored in ultrapure water at
−20◦C.
DNA oligonucleotide that was modified with a thiol
group on a two-carbon linker that was attached to the
backbone phosphate was purchased from FutureSynthesis
(Poznan, Poland). Depending on the target HIV-1 RT vari-
ant for cross-linking, the following variants of substrates
with modifications on a particular base (indicated by un-






Cross-linking of HIV-1 RT with RNA/DNA hybrids
Fluorescently labeled RNA oligonucleotides were ordered
fromFutureSynthesis (Poznan, Poland) and dissolved in ul-
trapure water with 0.5 mM EDTA. Complementary RNA
and DNA oligonucleotides were hybridized in the presence
of 100 mM NaCl. Cross-linking reactions that contained
4 M HIV-1 RT, 5 M substrate, 50 mM Tris (pH 7.4),
45 mMNaCl, 25 mMKCl and 30% glycerol were incubated
at 37◦C for 2 h, followed by 14 h at 24◦C. For the cross-
linking specificity test, the concentration of NaCl was in-
creased to 125 mM, and 5 mM DTT was included in the
reaction. Cross-linked samples were analyzed on NuPage
pre-cast Bis-Tris gradient gels (ThermoFischer Scientific).
Purification of cross-linked complexes
The cross-linking reaction mixture was diluted 5-fold with
500 mM NaCl, 50 mM NaPO4 (pH 7.8) and 10 mM imi-
dazole and loaded on a His-Trap column. The column was
washed with 50 mM NaCl, 50 mM NaPO4 (pH 7.8) and
10 mM imidazole. The complex was then eluted with 250
mM imidazole. The collected fraction was directly applied
to a heparin column that was equilibrated with 20 mM Tris
(pH 8.0), 50 mM NaCl and 0.1 mM EDTA. The purified
complex was collected in the flow-through. Excess free pro-
tein was eluted with 1 M NaCl. The complex was concen-
trated and stored in 10 mMMES (pH 6.5), 200 mM NaCl,
0.05 mM EDTA and 5 mM iodoacetamide.
RNase H activity assay for cross-linked complexes
Samples that contained 60 nM complexes were preincu-
bated at 37◦C for 30 min in standard solution (20 mM Tris
[pH 8.0] and 100 mM NaCl), with the NaCl concentration
increased to 500 mM or with the addition of 3 mg/ml hep-
arin. The cleavage reaction was performed at 37◦C for 0.5,
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5 or 20 min in the presence of 8 mMMgCl2 and stopped by
the addition of 40 mM EDTA. Similar reactions were per-
formed for 20min on samples that were preincubated for 1 h
at 37◦C in the presence of 20 mM DTT. The DTT concen-
tration was kept constant throughout the experiment. Hy-
drolysis products were analyzed on 20% denaturing TBE-
urea polyacrylamide gels and visualized by fluorescence
readout on a Typhoon Trio+ (GE Healthcare). To ana-
lyze the effect of incoming nucleotides on RNase H cleav-
age, the reactions were performed in the presence of hep-
arin and additionally contained a 100-fold molar excess of
2′-deoxycytidine-5′-([,]-imido)triphosphate (dCpNHpp;
Jena Biosciences, Jena, Germany).
Quenched flow experiments
Subsecond time-scale reactions were prepared using an
SFM-400 apparatus (BioLogic, Seyssinet-Pariset, France)
in quenched-flow mode. Solutions of 60 nM complex and
16mMMgCl2, both in 20 mMTris (pH 8.0), 100 mMNaCl
and 3 mg/ml heparin, were preincubated at 37◦C for 30
min. The reactionswere initiated bymixing the complex and
magnesium solution at 37◦C and stopped by the addition of
120 mM EDTA in a 1:1:1 volume ratio. Triplicate reactions
at time-points of 15, 20, 30, 40, 60, 80, 120, 160, 240 and
320 ms were collected. Hydrolysis products were analyzed
on 20% denaturing TBE-urea polyacrylamide gels and visu-
alized by fluorescence readout. Cleavage efficiency was es-
timated based on the densitometric quantification of reac-
tion products. To analyze the effect of incoming nucleotide
on RNase H cleavage, the reactions additionally contained
a 100-fold molar excess of dCpNHpp (Jena Biosciences).
Measurements of inhibition of complex formation by salt and
heparin
The assays were conducted in 96-well, black, flat-bottom
polystyrene NBS plates (Corning 3650) in a total reaction
volume of 100 l. The reaction buffer contained 100 mM
NaCl, 50 mM Tris (pH 8.0) and 5 mMCaCl2. For the mea-
surement of binding inhibition by salt, 10 l of HIV-1 RT
in reaction buffer was added to the plate wells to obtain fi-
nal concentrations of 1, 4, 7, 10, 25, 50, 120 and 250 nM,
and the concentration of NaCl in the buffer was increased
to 500 mM. For the measurement of binding inhibition by
heparin, the final concentration of HIV-1 RT was fixed at
120 nM, but the reaction contained heparin at a final con-
centration of 0–5 mg/ml. Afterward, 10 l of fluorescein-
labeled RNA/DNA hybrid substrates in H2O was added to
the reactions to a final concentration of 5 nM. The reac-
tions were prepared in triplicate. The reactionmixtures were
mixed by shaking for 5 s and incubated for 30 min at 25◦C.
Immediately after incubation, fluorescence anisotropy was
measured in aTecan InfiniteM1000 fluorescencemicroplate
reader at an excitation wavelength of 470 nm and emission
wavelength of 520 nm with a bandwidth of 5 nm. Binding
curves were fit in Prism 5 software (GraphPad, San Diego,
CA, USA) using the equation for one-site-specific binding.
Measurements of the affinity between cross-linked complexes
of HIV-1 RT and incoming nucleotides
The assay was conducted in 96-well, black, flat-bottom
polystyrene NBS plates (Corning 3650) in a total reaction
volume of 100 l. First, 10 l of cross-linked complexes in
reaction buffer (100 mMNaCl, 50 mMTris [pH 8.0], 5 mM
CaCl2 and 3 mg/ml heparin) was added to the plate wells
to obtain final concentrations of 1, 2.5, 5, 10, 25, 50 and
100 nM for saturation curves, followed by the addition of
10 l of Texas Red-labeled dCTP or dATP in H2O to a fi-
nal concentration of 5 nM. The reactions were prepared in
triplicate. The reaction mixtures were mixed by shaking for
5 s and incubated for 30 min at 25◦C. Immediately after in-
cubation, fluorescence anisotropy was measured in a Tecan
Infinite M1000 fluorescence microplate reader at an excita-
tion wavelength of 590 nm and emission wavelength of 612
nm with a bandwidth of 5 nm. Binding curves were fit in
Origin software (OriginLab, Northampton, MA, USA) us-
ing the equation for one-site-specific binding, and the Kd
was estimated.
The binding affinity between cross-linked complexes and
dCpNHpp was measured by thermophoresis. The reaction
buffer contained 100 mM NaCl, 50 mM Tris (pH 8.0),
5 mM CaCl2 and 3 mg/ml heparin. A series of 1:1 di-
lutions of dCpNHpp were prepared starting from 5 M.
The dCpNHpp dilutions were then mixed in a 1:1 ratio
with 50 nM solutions of the cross-linked complex. The
samples were incubated for 20 min at room temperature
and loaded into capillaries. The measurements were per-
formed usingMonolith-NT.115 reader (NanoTemper Tech-
nologies,Mu¨nchen,Germany), based on the fluorescent sig-
nal from the Cy5 label on the 5′ end of the RNA strand
of the cross-linked substrate. The data were analyzed using
NanoTemper Analysis software, and the Kd was calculated.
RESULTS
Molecular dynamics simulations
We used MD simulations to test whether the hybrid sub-
strate can adopt a conformation that allows for the simul-
taneous interaction with both active sites of HIV-1 RT and
to determine the corresponding conformation of the nucleic
acid. For our MD simulations, we used the 4PQU struc-
ture (20), in which the RNA/DNA substrate interacts only
with the polymerase active site and is thus in the polymerase
mode. We added a missing protein helix of the RNase H
domain (aa 546–554; taken from the 1RTD structure) to
the structure and reverted the D498N substitution. Finally,
we extended the RNA/DNA substrate to 26 bp. Using this
model, we performed a 100 ns MD simulation, in which
we imposed a series of distance restraints to promote the
catalytic interaction between the substrate and the HIV-1
RT RNase H domain. The restraints were based on the
structures of substrate complexes of cellular RNases H1
(29,30) and included catalytic interactions between the scis-
sile phosphate of the RNA and the active site and a cru-
cial interaction between a phosphate-binding pocket ele-
ment and the DNA phosphate group of nt −3. In all of our
analyses, we used nucleotide numbering relative to the pre-
ferred RNase H cleavage site 18 nt from the 3′-end of the
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DNA primer. The details of the restraints are given in the
Materials and Methods. We emphasize that the use of re-
straints was not meant to polish the simulations but rather
to obtain structural conditions that correspond to the cat-
alytic interaction of the hybrid with the RNase H domain
within an affordable computational time and in the absence
of a suitable experimentally determined geometry.
The simulations showed that the substrate could be neatly
brought to the catalytic interaction with theRNaseH active
site, equivalent to the one that was conserved for cellular
RNases H1 (Figure 2A–C, Supplementary Movie 1). Im-
portantly, although no restraints were used to preserve the
contact between the substrate and the polymerase domain,
the substrate was stably bound at the polymerase active site
throughout the simulation, including preservation of the in-
coming nucleotide and metal ion binding. This implies that
the interaction with the RNase H active site did not per-
turb the binding of the primer end at the polymerase ac-
tive site. Similar behavior was observed for simulations with
RNA/DNA hybrids of various sequences (M. Figiel et al.,
in preparation). To test our simulation results on a longer
timescale, we extended the simulation length from 100 ns to
1 s. We also conducted four additional simulations, each
300 ns long, to verify convergence. The extended simulation
time fully confirmed the initial result.
To characterize the substrate conformation change that
was required to bring the nucleic acid in the catalytic in-
teraction with the RNase H domain, we compared the val-
ues of the parameters that described the helical geometry
of the RNA/DNA hybrid in the polymerase mode struc-
ture (4PQU) with average values of the same parameters
throughout the MD simulation. In the simulation, we did
not observe any significant global substrate bending. Over-
all, the DNA strand underwent much larger conforma-
tional changes than RNA, in agreement with higher rigid-
ity of the RNA. All of the major conformational changes
in the hybrid occurred in the vicinity of the RNase H do-
main, and the substrate at the polymerase domain remained
virtually unchanged (Figure 2). The main conformational
change in the nucleic acid that was observed was untwist-
ing of the double helix. In the crystal structure of the poly-
merase mode (4PQU), the phosphate of nt −4 was located
in the vicinity of the phosphate-binding pocket. Bringing
the phosphate of nt −3 into the pocket required untwisting
the substrate, which occurred in the segment of the hybrid
that comprised nucleotides −9 to −1 (Figure 2D). This sec-
tion of the hybrid was unwound by a total of 24◦. Another
change that we observed during the MD simulation was
narrowing of the minor groove width, particularly for nu-
cleotides−3 and−2 (Figure 2E). The requirement of minor
groove narrowing was in agreement with the results of pre-
viously published biochemical experiments that used sub-
strates with doublet insertions of locked nucleic acid in the
DNA strand (31). Locked nucleic acids lock the substrate
in the A-form conformation with a wide minor groove, and
their introduction in the −4 to −1 region blocked RNase H
cleavage.
In the course of the simulation, we also observed con-
formational changes in the protein, including movements
of the thumb and finger subdomains of the polymerase do-
main, which are known to be mobile (19), and movement of
the RNase H domain toward the RNA backbone (Figure
2C). In fact, it was this movement that positioned the RNA
scissile phosphate at the active site of the RNase H domain
rather than changes in the position of the RNA strand.
We compared the conformational changes that were ob-
served during the course of our simulation with the dif-
ferences that were observed between crystal structures of
HIV-1 RT substrate complexes in polymerase andRNase H
modes. The global changes in the RNA/DNA configura-
tion in our MD simulations and between the crystal struc-
tures were different, which was expected because of the
different behavior of the hybrid at the polymerase active
site. However, a common element was the untwisting of the
hybrid that was observed both between the pairs of crys-
tal structures and in our simulation. Therefore, we con-
clude that hybrid untwisting is a critical element of the
RNA/DNA conformational change that allows productive
interactions with the RNase H active site without perturb-
ing hybrid binding at the polymerase domain. Most impor-
tantly, removal of the substrate from the polymerase active
site is not required for catalytic interaction of the nucleic
acid with the RNase H domain.
Preparation of cross-linked complexes of HIV-1 RT and
RNA/DNA hybrid substrates
We next experimentally tested whether the substrate can si-
multaneously interact with both active sites of HIV-1 RT.
We immobilized the substrate at the polymerase active site
of HIV-1 RT using chemical cross-linking and evaluated
whether RNase H cleavage can still occur within such a co-
valently tethered complex.We chose a cross-linkingmethod
that relies on the formation of a disulfide linkage between
a cysteine residue that is introduced to the protein by site-
directed mutagenesis and a thiol group that is attached to
either the backbone or base of the DNA (32,33) (Supple-
mentary Figure S1). For cysteine substitution, we selected
two residues at and in the vicinity of the polymerase active
site that are sufficiently close to theRNA/DNA substrate in
the polymerase mode (structure 4PQU) for chemical cross-
linking to occur, but in theRNaseHmode (structure 4B3O)
are too far from the substrate for disulfide formation (Fig-
ure 3, Supplementary Figure S2). The first residue that was
selected for through-backbone cross-linking was Asp186.
In the 4PQU structure, the sidechain of Asp186 is located
close to the DNA phosphate between the last and penulti-
mate nucleotides of the primer. The second residue,Met184,
which is located in the vicinity of the last and penultimate
bases of the primer in polymerase mode, was selected for
the through-base reaction (described in detail in the Sup-
plementary Data). Both Asp186 andMet184 are part of the
highly conserved 183-YMDD-186 polymerase active site
motif. As a reference residue, we selected Gln258, which is
located in the thumb subdomain of the polymerase domain
and close to the base of the 6th nucleotide of the primer
(from the 3′-end) in both the polymerase and RNase H
modes (Figure 3, Supplementary Figure S2E and F). In
fact, HIV-1 RT substrate complexes that contain this cross-
link have been crystallized in both modes (18,20). There-
fore, we used Q258C cross-linked complexes as a reference
in which both modes are allowed. As a control for the speci-
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Figure 2. Molecular dynamics (MD) simulation of HIV-1 RT–hybrid substrate complex. (A) Superposition of starting model (p66 in cyan; p51 in light
gray; RNA/DNA in light shades of red and blue, respectively) and final model inMD simulations (p66 in orange; p51 in darker gray; RNA/DNA in darker
shades of red and blue, respectively). The starting model was based on the crystal structure of HIV-1 RT bound to RNA/DNA substrate in polymerase
mode (PDB ID: 4PQU), modified by extending the RNA/DNA substrate by 4 bp. Residues that form the active sites are shown as sticks. Scissile phosphates
and phosphates bound in the phosphate binding pocket are shown as spheres. Incoming nucleotides are shown in purple and yellow for the 4PQU structure
and the MD model, respectively. Magnesium ions are shown as dark green spheres for the starting MD model and green spheres for the final MD model.
Movements of the thumb and RNase H domains in the MD simulation are indicated with arrows. (B) Close-up of the phosphate-binding pockets of the
starting and final MDmodels. Residues that form the phosphate-binding pocket are shown as sticks and labeled. The positions of the phosphate group of
nt −3 in the beginning of the simulation and at its end are indicated by spheres. The direction of movement of the DNA strand is indicated with an arrow.
(C) Close-up of the RNase H active sites of the starting and final MD models. Active site residues are shown as sticks. Scissile phosphates are shown as
spheres. The direction of movement of the RNase H domain is indicated with an arrow. (D and E) Analysis of conformational changes in the RNA/DNA
substrate in the course of the MD simulation. (D) Plot of helical twist difference. Helical twist values were summed along the helix for the 4PQU structure
and for average values during MD simulation. The difference of these sums between the MD model and 4PQU structure is plotted for each residue (twist
accumulation difference). Base pairs are numbered according to their position relative to the scissile phosphate. (E) Minor groove width of the RNA/DNA
substrate in the 4PQU structure (blue squares) and average minor groove width during the MD simulation (purple circles).
ficity of our approach, we used Tyr183. Although located
immediately next toMet184, according to the distance anal-
ysis, Y183C should not form a through-base cross-link with
a hybrid in a non-strained conformation (Supplementary
Table S1).
We also considered an inverse approach, in which the
complex is cross-linked at the RNase H domain and poly-
merase activity is monitored. However, inspection of the
structural data indicated that although the cross-linking
strategy could be designed, it would not discriminate be-
tween the polymerase and RNase H modes. In such a case,
the cross-link would form both when the substrate was en-
gaged at the active site of RNase H and when the RNAwas
located too far from it for catalysis to occur, as observed in
the 4PQU structure (polymerase mode). Therefore, we fol-
lowed only the approach of immobilizing the substrate at
the polymerase active site.
We prepared a set of RNA/DNA hybrids with a random
sequence and a double-stranded region of 24 bp. Schemes of
the substrates are shown in Figure 3. TheRNA strand of the
hybrids contained Cy5 at its 5′-end and fluorescein at the 3′-
end to visualize the cleavage products. HIV-1 RT is known
to preferentially position the recessed 3′-end of the DNA at
the polymerase active site (3′-end-directed binding). There-
fore, to better define the register of substrate binding, we
introduced 6-nt 5′ overhangs to the RNA strand of the hy-
brids to create a recessed 3′ terminus of theDNA. Four vari-
ants of the DNA strand were prepared that differed in the
type and position of the modification. In the first variant of
the substrate, CL3.b, which was intended for experiments
with D186C, the phosphate group between the last and
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Figure 3. Schematic of the design of cross-linking chemistry. The p66 subunit is shown in orange, with the RNase H domain indicated with a darker
shade. The polymerase and RNase H active sites are represented by purple and green circles, respectively. DNA and RNA strands of the hybrid substrate
are shown in blue and red, respectively. Yellow circles indicate residues that were individually substituted with cysteines for cross-linking. Their position
relative to the relevant DNAmodification is shown in the close-ups. The chemical modification that contained a thiol group is indicated in magenta (sticks
represent modified bases; circles represent modified backbone phosphates). The disulfide linkage between the thiol groups of the cysteine and modified
phosphate/base is indicated as a cyan line. Sequences of the substrates are shown for each cross-linking reaction. Base-modified nucleotides are shown in
magenta. The magenta circle indicates the position of the modified backbone phosphate.
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Figure 4. Specificity of the cross-linking approach and purification of
cross-linked complexes. (A) Cross-linking of M184C and Y183C vari-
ants of HIV-1 RT to base-modified substrates in the presence of 125 mM
NaCl and 5 mM DTT. Lane 1, molecular weight marker; lanes 2–4, re-
actions with M184C; lanes 5–7, reactions with Y183C. Substrates in the
cross-linking reaction are indicated above the gel. C, no substrate added.
The band that corresponds to the cross-linked product is indicated with
an asterisk. (B) Example of cross-linked complex purification (HIV-1 RT
D186Cwith CL3b).M,molecular weightmarker; RT,HIV-1RT; CL, sam-
ple after cross-linking reaction in 45 mM NaCl and without DTT; NE,
nickel elution;HF, heparin column flow-through;HE, heparin column elu-
tion. The band that corresponds to the cross-linked product is indicated
with an asterisk.
penultimate nucleotides of the primer was modified with a
thiol group on a two-carbon linker (Figure 3, Supplemen-
tary Figure S2). The other two versions of this substrate,
CL3.1 and CL3.2, which were intended for cross-linking
withM184C andY183C variants, contained the samemod-
ification on a guanine in the last nucleotide (with an appro-
priate change in sequence) or penultimate nucleotide (Fig-
ure 3, Supplementary Figure S2). The fourth variant, CL3,
which was intended for experiments with Q258C, contained
a base modification in the 6th nucleotide from the 3′-end.
To obtain cross-linked complexes, we incubated HIV-1
RT D186C, M184C, Y183C and Q258C variants with ap-
propriately modified oligonucleotides, and formation of the
complex was monitored by non-reducing sodium dodecyl
sulphate-polyacrylamide gel electrophoresis. As explained
above, our analysis of the structures predicted that cross-
linked complexes should form for the M184C variant with
CL3.1 and CL3.2 substrates but not for the same hybrids
with Y183C protein. Indeed, in the presence of 5 mMDTT
and 125 mM NaCl, we observed cross-linked species only
for M184C and not for Y183C (Figure 4A), which con-
firmed the specificity of our approach.
RNase H activity within the cross-linked complexes
To study RNase H activity within the cross-linked com-
plexes, we purified HIV-1 RT D186C, M184C and Q258C
variants that were tethered to appropriately modified CL3
substrates (Figure 4B). Each protein variant wasmixedwith
the corresponding RNA/DNA hybrid at a 1:1.25 molar ra-
tio in a buffer without DTT to increase the reaction yield,
and the mixture was incubated overnight. After the reac-
tion, ∼50% of the p66 subunit was cross-linked with the
hybrid (Figure 4B). The purification protocol for the cross-
linked complex comprised two steps. First, the sample was
loaded onto a nickel column in the presence of 0.5MNaCl.
All protein-containing species were captured on the column
and the buffer with high salt concentration washed away
any nucleic acid that was not covalently linked to the pro-
tein. Second, the fraction that was eluted from the nickel
column with a buffer with high imidazole concentration
and that contained both free and cross-linked protein was
passed through a heparin column. The free protein bound
to the resin, and the cross-linked protein-substrate com-
plexes were collected as the flow-through fraction (Figure
4B).
Purified complexes were used in RNase H activity as-
says. We sought to exclude the possibility that some of the
observed activity resulted from a reaction that was cat-
alyzed by non-covalent complexes that either co-purified
with the cross-linked species or appeared over time because
of cross-link breakage. We used heparin as a substrate com-
petitor (trap) or a high NaCl concentration, which pre-
vents protein–RNA/DNA interactions. Using fluorescence
anisotropy measurements we verified that 3 mg/ml hep-
arin or 0.5 M NaCl completely inhibited substrate binding
by HIV-1 RT (Supplementary Figure S3). For each cross-
linked complex, RNase H cleavage was initiated by the ad-
dition of Mg2+, the essential co-factor. Aliquots of reac-
tions with and without high salt or heparin trap were with-
drawn at time points between 30 s and 20 min. The reac-
tions were terminated with EDTA, and the reaction prod-
ucts were analyzed on TBE-urea gels with fluorescence vi-
sualization. The results showed efficient RNase H cleavage
for all four cross-linked complexes:M184C-CL3.1,M184C-
CL3.2, D186C-CL3b and Q258C-CL3 (Figure 5A). At the
shortest time of 30 s, up to 55% of the substrate was already
converted to cleavage products. As a control, similar reac-
tions were performed with complexes that were pretreated
with 20 mM DTT, which caused breakage of the disulfide
bond either in the whole population of complexes or a part
of it, depending on the protein variant that was used. In
such samples, new cleavage products were observed. These
cleavages were performed by the free enzyme that dissoci-
ated from the substrate and bound it with a different regis-
ter. The addition of salt or heparin did not affect RNase H
cleavage in the cross-linked complexes. However, in the sam-
ples that were pretreated with DTT, the addition of salt
or heparin strongly inhibited the reaction and completely
eliminated off-register cleavage. This confirmed that the ad-
dition of either a high salt concentration or heparin trap
restricted the observed activity exclusively to chemically
cross-linked complexes. In conclusion, immobilization of
the substrate at the active site of the polymerase did not pre-
clude RNase H cleavage.
To exclude the possibility that the observed cleavage re-
sulted from rare rearrangements of the enzyme–substrate
complex that occurred only during the prolonged times of
our experiment, we studied the reaction with the addition of
heparin at shorter times, ranging from 15 to 320 ms, using
a quenched-flow apparatus (Figure 5B). The product was
already observed at the shortest time of 15 ms, indicating
that a conformation that allowed simultaneous interactions
with the two active sites was not a rare event. The reac-
tion proceeded with similar kinetics for all four complexes:
D186C-CL3b, M184C-CL3.1 and M184C-Cl3.2 in which
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Figure 5. RNase H cleavage within cross-linked HIV-1 RT–substrate complexes. (A) RNase H cleavage within cross-linked complexes on a minute time-
scale. The protein variant and cross-linked hybrid are indicated on top of the gels. For M184C, two substrates were used with a modification in the last
nucleotide (CL3.1) or penultimate nucleotide (CL3.2) of the DNA strand. Reactions were performed for 0.5, 5 or 20 min in the presence of 3 mg/ml heparin
(H) or 0.5 M NaCl (NaCl). Reactions in the presence of 20 mM DTT (D) were performed for 20 min. The reactions were stopped with the addition of
EDTA and analyzed on 20% TBE-urea denaturing gels. M, marker (Cy5-labeled 24-mer RNA, corresponding to the product of the cleavage 18 nt from
the 3′-end of the primer); 0, unreacted complex. The triangle indicates increasing time from 30 s to 20 min. Yellow bands correspond to the intact substrate
with both fluorescent labels. Green and red bands correspond to cleavage products that comprised 5′ Cy5 or 3′ fluorescein, respectively. (B) RNase H
cleavage within cross-linked complexes on a sub-second time-scale. The reactions were performed using a quenched-flow apparatus. The cleaved fraction
of the substrate was quantified by densitometry. Data from three independent experiments were averaged and plotted for each time-point. (C) RNase H
cleavage of CL3 within cross-linked complexes in the presence of a non-hydrolyzable incoming nucleotide. The analysis was performed as in (B).
the nucleic acid was locked at the polymerase active site and
Q258C-CL3 in which the substrate could be displaced from
the polymerase active center. These results indicate that dis-
placement of the substrate from the polymerase active site
was not required for RNase H cleavage and thus the sub-
strate could interact with both active sites simultaneously.
Organization of the polymerase active site
We then sought to provide additional support for the si-
multaneous interaction of the substrate with both active
sites. In particular, we wanted to exclude the possibility
that RNase H activity within cross-linked complexes was
attributable to transient substrate displacement from the
polymerase active site. Within cross-linked complexes, the
primer end is tethered to the protein, so such displace-
ment would only be possible with structural distortion of
the RNA/DNA helix and protein structure at the poly-
merase active site. We decided to determine whether the in-
coming nucleotide can bind to the cross-linked complexes
and whether this binding affects RNase H activity. We rea-
soned that binding of the nucleotide would confirm that the
polymerase active site is properly organized, including the
protein residues and substrate end. Moreover, nucleotide
binding would stabilize the substrate at the polymerase ac-
tive site. Therefore, if substrate displacement from the poly-
merase active site is necessary for RNase H activity, then
bound nucleotide would inhibit RNase H cleavage.
We first tested whether our Q258C-CL3 and M184C-
CL3.1 cross-linked complexes bind dNTP. Fluorescence
anisotropy was used to measure the affinity of incoming nu-
cleotides that were labeled with Texas Red for these com-
plexes (Supplementary Figure S4). Ca2+ ions that mimic
Mg2+ at the active site but do not promote polymerization
were used to block incorporation of the nucleotide in these
assays. Fluorescent dCTP analog, which would base pair
with the templateG at the polymerase active site, was bound
by both complexes (Kd = 3.6 ± 2.0 nM and 3.3 ± 2.0 nM
for Q258C-CL3 and M184C-CL3.1, respectively). This in-
teraction was specific because no binding within the ana-
lyzed concentration range was observed for the mismatched
dATP analog. As an alternative approach to test nucleotide
binding, we measured the affinity between cross-linked sub-
strate complexes of HIV-1 RT and a non-hydrolyzable ana-
logue of dCTP (dCpNHpp) in the presence of Ca2+ ions
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using a thermophoresis method. The Kd values were 12.0
± 0.6 nM and 19.5 ± 0.6 nM for Q258C-CL3 and M184C-
CL3.1, respectively (Supplementary Figure S5). These val-
ues were very similar to the Kd of 18 nM that was pre-
viously reported for the free protein (34). They were also
slightly different from those obtained using the fluorescent
nucleotides, but this was expected when considering the dif-
ferences in chemical structures of the two types of the dNTP
analogs.
For efficient and specific binding of the incoming nu-
cleotide, all of the elements of the polymerase active site
need to be properly aligned. The divalent metal ions (Mg2+
or Ca2+) at the active site coordinate the phosphate groups.
Incoming nucleotide base stacking requires the correct ori-
entation of the DNA primer and proper organization of the
active site residue Arg72. Finally, base pairing of the in-
coming nucleotide requires appropriate orientation of the
RNA template. The fact that the cross-linked complexes
bound the incoming nucleotide indicates that all of the
above requirements were met, and the architecture of the
polymerase active site with regard to both protein confor-
mation and substrate binding was not perturbed.
After establishing that the cross-linked complexes bind
the incoming nucleotide, including its non-hydrolyzable
analog, we tested whether its addition, which would re-
sult in stabilization of the primer end at the polymerase
active site, affected RNase H cleavage. The results of the
quenched-flow experiments showed that the presence of
dCpNHpp did not affect the kinetics of RNase H cleavage
within Q258C-CL3 and M184C-CL3.1 complexes (Figure
5C). Similarly, no effect on cleavage efficiency was observed
when the reactions were performed for longer times (Sup-
plementary Figure S6). Additionally, the pattern of cleav-
age remained unchanged, suggesting that multiple cuts re-
sulted from the mobility of the RNase H domain rather
than translocation of the substrate in the complex, which
would be blocked by binding of the incoming nucleotide.
These results confirm that displacement of the substrate
from the polymerase active site is not required for RNase H
cleavage and thus our computational and experimental re-
sults are in agreement.
DISCUSSION
Coordination of the polymerase and RNase H activities of
RTs is a critical element of their mechanism of action and
essential for the proper execution of reverse transcription.
In particular, access of the substrate to the RNase H ac-
tive site needs to be restricted. This is important for the ex-
ecution of specialized and specific cleavage events, such as
PPT generation (M. Figiel et al., in preparation). For HIV-
1 RT, coordination of the two enzymatic activities relies on
conformational changes in the protein-substrate complex
(19), the detailed mechanism of which has been unclear. In
this report, we used a chemical cross-linking approach and
MD simulations to show that a complex of HIV-1 RT with
RNA/DNA can adopt a conformation in which the sub-
strate interacts with the active site of the polymerase and is
simultaneously catalytically bound at theRNaseHdomain.
An indication of such a simultaneous interaction, although
not explicit, was provided by studies using RT-RNA/DNA
complexes in which the substrate was stabilized at the poly-
merase active site through binding of the pyrophosphate
analog inhibitor (35). However, a quantitative analysis of
these data was not performed, and the possibility of tran-
sient rearrangement of this dynamic complex that allowed
RNase H cleavage through substrate displacement from the
polymerase active site could not be fully excluded. While
the present report was under review, a study by Li et al. was
published that described a pre-steady-state kinetic analysis
of HIV-1RT activity (36). The authors monitored concomi-
tant DNA polymerization and RNase H cleavage by HIV-
1 RT and used complex models of all possible transitions
and reactions in this system together with global fitting
to determine the corresponding kinetic parameters. They
found that nucleotide incorporation and RNase H cuts oc-
curred simultaneously and that both active sites interacted
with the substrate in most HIV-1 RT–substrate complexes.
Li et al. also found that the rate of polymerization was
limited by pyrophosphate release (37), and RNA hydroly-
sis was limited by the requirement for an intact stretch of
RNA downstream of the cleavage site. When these two el-
ements were taken into account, the rates of polymeriza-
tion and RNase H cuts during reverse transcription were
comparable. Therefore, the single-turnover kinetic data are
in full agreement with the simultaneous mode we describe
herein. Our approach employing chemical tethering of the
substrate at the polymerase active site provides a more di-
rect, structure-based evidence of a simultaneous interaction
between the substrate and the two active sites. Additionally,
our MD simulations allowed us to characterize the confor-
mation that the complex adopts in the simultaneous mode.
RNase H cuts have been shown to occur when polymer-
ization of the DNA pauses (10–12). Pausing was previously
presumed to be required to enable the substrate to disen-
gage from the polymerase active site to allow the RNase H
to perform cleavage. Our data suggest a different possibility.
Polymerase pausing may give the complex sufficient time to
undergo the conformational change that was observed in
our MD simulations, which does not require substrate re-
moval from the polymerase active site but still allows cat-
alytic RNase H–substrate interactions. In fact, stronger in-
teractions of the hybrid with the RNase H domain that re-
sulted from this conformational change may further hin-
der substrate translocation and lengthen the pause of poly-
merization, leading to even tighter coupling of polymerase
pausing andRNaseH cuts. Therefore, our data are in agree-
ment with coupling of polymerase pausing and RNase H
cuts, and substrate removal from the polymerase active site
does not need to be invoked to explain this relationship.
The activity of HIV RNase H can be influenced by mul-
tiple factors. Among these are mutations in regions that are
distant from the active sites and the substrate binding cleft
(e.g. (38)) or the addition of nucleocapsid protein (39). The
sequence of the RNA/DNA substrate can also greatly im-
pact RNase H cleavage that is important for PPT genera-
tion. The effect of many of these factors can be explained
by considering the way in which they affect conformational
changes in the RT–substrate complex that are required for
RNase H activity.
Two types of retroviral RTs have been described based
on the architecture of the active molecule: dimeric and
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monomeric. In dimeric RTs, such as the HIV-1 enzyme, the
RNase H domain is placed within the structure of the het-
erodimer, and its movements are restricted. In contrast, in
monomeric RTs, such as the one from Moloney leukemia
virus, polymerase and RNase H domains are tethered by a
flexible linker, and the RNase H domain can move freely
(40). Therefore, the regulation of access of RNase H to
the substrate is different in dimeric and monomeric en-
zymes. For HIV-1 RT, the conformational changes in the
RNA/DNA hybrid that are described herein are used to
restrict the amount of RNase H activity. For monomeric
enzymes, RNase H activity is limited because the mobile
RNase H domain only occasionally interacts with the sub-
strate and cleaves it. Despite this difference, the mechanism
of the reverse transcription reaction is the same for both
types of RTs. For example, the PPT sequences of HIV-1 and
Moloney leukemia virus are very similar; in some cases, they
can be used interchangeably by the two enzymes (41,42).
Therefore, RTs from related retroviruses can use different
mechanisms to modulate RNase H activity.
In summary, we devised a unique approach that com-
bined MD with enzymatic studies of chemically cross-
linked protein–nucleic acid complexes to demonstrate the
existence of a conformation of the HIV-1 RT–substrate
complex that has not been observed in crystal struc-
tures. It involves simultaneous interactions between the
RNA/DNAand both polymerase andRNaseHactive sites.
Such high energy states that cannot be captured in crystal
structures but are relevant to the enzyme’s mechanism likely
also exist for other nucleic acid enzymes withmultiple activ-
ities. Our work provides a conceptual and methodological
approach for studies of such transient states.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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